SIRT6 is a sirtuin protein crucial for DNA repair, genomic stability, and metabolic regulation. Gene therapy aims to increase SIRT6 levels, which has been shown in animal models to extend lifespan and healthspan by bolstering these core cellular maintenance processes that degrade with age. This intervention directly targets multiple hallmarks of aging, representing a potentially foundational approach to longevity.
Verdict
A highly promising but purely experimental therapy with significant unknown risks.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Very High
EVIDENCE GRADE
C
MONTHLY COST
$1000000 - $4000000
Protocol
- A single administration of a viral vector (e.g., AAV) to introduce additional copies of the SIRT6 gene.
Flags
- Currently not available outside of research settings.
- Uses viral vectors (e.g., AAV) which carry risks of a significant immune response.
- Potential for insertional mutagenesis, which can increase long-term cancer risk.
- Long-term effects and safety profile in humans are completely unknown.
- Extremely high theoretical cost and inaccessible to the public.